多发性骨髓瘤病人衰弱评估的研究进展

doi:10.3969/j.issn.1003-9198.2025.05.020

摘要/Abstract

摘要： 衰弱是一种常见的老年综合征,影响多发性骨髓瘤治疗的有效性和安全性。衰弱的筛查对多发性骨髓瘤治疗方式的选择和不良事件风险预测尤为重要。该文归纳了衰弱评估的概念模型、潜在生物标志物及多发性骨髓瘤病人衰弱评估工具,并分析了各种评估方式对于多发性骨髓瘤病人的优缺点和临床应用价值,指出衰弱可作为多发性骨髓瘤病人风险的预测指标,但未来研究仍需进一步完善针对多发性骨髓瘤病人衰弱的评估指标,提高其在多发性骨髓瘤病人中的应用价值。

关键词: 多发性骨髓瘤, 衰弱, 生物标志物, 评估工具, 预测指标

Abstract: Frailty is a common geriatric syndrome that significantly affects the efficacy and safety of treatment in the patients with multiple myeloma. Screening for frailty is particularly important for the selection of treatment methods and the prediction of adverse event risks for multiple myeloma. This article summarizes the conceptual model and potential biomarkers of frailty, and frailty assessment tool for the patients with multiple myeloma, and analyzes the advantages, disadvantages and clinical application value of various assessment methods for multiple myeloma. It points out that frailty can be used as a predictor of risk in the patients with multiple myeloma. However, future studies still need to further refine the evaluation indicators of frailty in the patients with multiple myeloma, and to improve its application value for multiple myeloma.

Key words: multiple myeloma, frailty, biomarker, assessment tool, predictive indicator

中图分类号:

R 733.3

高敬宇, 王婷, 谭思敏. 多发性骨髓瘤病人衰弱评估的研究进展[J]. 实用老年医学, 2025, 39(5): 534-538.

GAO Jingyu, WANG Ting, TAN Simin. Research advance of frailty assessment in patients with multiple myeloma[J]. Practical Geriatrics, 2025, 39(5): 534-538.

参考文献

[1] TOPINKOVÁ E. Aging, disability and frailty[J].Ann Nutr Metab, 2008, 52(Suppl 1): 6-11.
[2] FRIED L P, TANGEN C M, WALSTON J, et al.Frailty in older adults: evidence for a phenotype[J]. J Gerontol A Biol Sci Med Sci, 2001, 56(3): M146-M156.
[3] STEGE C A M, VAN DER HOLT B, DINMOHAMED A G, et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities[J]. Leukemia, 2020, 34(7): 1964-1966.
[4] NATHWANI N, KURTIN S E, LIPE B, et al. Integrating touchscreen-based geriatric assessment and frailty screening for adults with multiple myeloma to drive personalized treatment decisions[J]. JCO Oncol Pract, 2020, 16(1): e92-e99.
[5] BRIOLI A, MANZ K, PFIRRMANN M, et al. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)[J]. J Cancer Res Clin Oncol, 2020, 146(3): 749-759.
[6] MIAN H, WILDES T M, VIJ R, et al. Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study[J]. Blood Cancer J, 2023, 13(1): 76.
[7] FACON T, COOK G, USMANI S Z, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA[J]. Leukemia, 2022, 36(4): 1066-1077.
[8] SIM S, KALFF A, TUCH G, et al. The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia[J]. Intern Med J, 2023, 53(5): 819-824.
[9] PAFFENBARGER R S Jr, BLAIR S N, LEE I M, et al. Measurement of physical activity to assess health effects in free-living populations[J]. Med Sci Sports Exerc, 1993, 25(1): 60-70.
[10] ROCKWOOD K, MITNITSKI A. Frailty in relation to the accumulation of deficits[J]. J Gerontol A Biol Sci Med Sci, 2007, 62(7): 722-727.
[11] PATEL B G, LUO S, WILDES T M, et al. Frailty in older adults with multiple myeloma: a study of US veterans[J]. JCO Clin Cancer Inform, 2020, 4: 117-127.
[12] MIAN H S, WILDES T M, FIALA M A. Development of a medicare health outcomes survey deficit-accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma[J]. JCO Clin Cancer Inform, 2018, 2: CCI.18.00043.
[13] VALDIGLESIAS V, SÁNCHEZ-FLORES M, MARCOS-PÉREZ D, et al. Exploring genetic outcomes as frailty biomarkers[J]. J Gerontol A Biol Sci Med Sci, 2019, 74(2): 168-175.
[14] ARAÚJO CARVALHO A C, TAVARES MENDES M L, DA SILVA REIS M C, et al. Telomere length and frailty in older adults-a systematic review and meta-analysis[J]. Ageing Res Rev, 2019, 54: 100914.
[15] ZHOU J, WANG J, SHEN Y, et al. The association between telomere length and frailty: a systematic review and meta-analysis[J]. Exp Gerontol, 2018, 106: 16-20.
[16] 郑文婕, 童坦君, 张宗玉. 细胞衰老的重要通路: p16INK4a/Rb和p19ARF/p53/p21Cip1信号途径[J]. 生命的化学, 2002, 22(4): 314-316.
[17] MATJUSAITIS M, CHIN G, SARNOSKI E A, et al. Biomarkers to identify and isolate senescent cells[J]. Ageing Res Rev, 2016, 29: 1-12.
[18] FULOP T, MCELHANEY J, PAWELEC G, et al. Frailty, inflammation and immunosenescence[J]. Interdiscip Top Gerontol Geriatr, 2015, 41: 26-40.
[19] VATIC M, VON HAEHLING S, EBNER N. Inflammatory biomarkers of frailty[J]. Exp Gerontol, 2020, 133: 110858.
[20] 刘慧珍, 王娜, 商娜, 等. 血清白细胞介素-6、沉默信息调节因子-1与衰弱的相关性研究[J]. 中华急诊医学杂志, 2024, 33(5): 677-682.
[21] 潘一鸣, 马丽娜, 李耘. 老年人衰弱综合征相关炎症标记物的研究进展[J]. 实用老年医学, 2021, 35(4): 427-430.
[22] CHEW J, TAY L, LIM J P, et al. Serum myostatin and IGF-1 as gender-specific biomarkers of frailty and low muscle mass in community-dwelling older adults[J]. J Nutr Health Aging, 2019, 23(10): 979-986.
[23] 寇夕, 刘永宏, 董玮, 等. 住院老年病人衰弱综合征与胰岛素样生长因子-1的相关性研究[J]. 实用老年医学, 2024, 38(5): 474-477.
[24] CRUZ-JENTOFT A J, SAYER A A. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646.
[25] 陈添雅, 宋芬, 刘玥. 床旁肌肉超声评估老年患者衰弱的研究进展[J]. 临床麻醉学杂志, 2024, 40(10): 1089-1094.
[26] MILANI P, VINCENT RAJKUMAR S, MERLINI G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma[J]. Am J Hematol, 2016, 91(11): 1129-1134.
[27] GIRI S, DAHAL S, BAL S, et al. Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma[J]. J Geriatr Oncol, 2022, 13(4): 486-492.
[28] ENGELHARDT M, DOLD S M, IHORST G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores[J]. Haematologica, 2016, 101(9): 1110-1119.
[29] ENGELHARDT M, DOMM A S, DOLD S M, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients[J]. Haematologica, 2017, 102(5): 910-921.
[30] GIRI S, WILLIAMS G, ROSKO A, et al. Simplified frailty assessment tools: are we really capturing frailty or something else?[J]. Leukemia, 2020, 34(7): 1967-1969.
[31] ABE Y, KOBAYASHI T, USUI Y, et al. N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma[J]. Oncotarget, 2019, 10(10): 1160-1170.
[32] 李玉军. 老年多发性骨髓瘤临床特征、预后及衰弱评估分析[D]. 保定: 河北大学, 2022.
[33] ROCKWOOD K. A global clinical measure of fitness and frailty in elderly people[J]. Can Med Assoc J, 2005, 173(5): 489-495.
[34] PALUMBO A, BRINGHEN S, MATEOS M V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report[J]. Blood, 2015, 125(13): 2068-2074.
[35] ZHANG Y, LIANG X, XU W, et al. Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study[J]. J Hematol Oncol, 2024, 17(1): 48.
[36] 薛茹. 不同衰弱评分下老年多发性骨髓瘤患者化疗疗效及安全性评估[D]. 太原: 山西医科大学, 2021.
[37] ROSKO A E, HUANG Y, BENSON D M, et al. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant[J]. J Geriatr Oncol, 2019, 10(3): 479-485.
[38] 陈延梅, 郭红, 焦萌, 等. 老年衰弱人群跌倒发生率的Meta分析[J]. 中国实用护理杂志, 2024, 40(16): 1275-1281.